Outsourcing innovation in healthcare
Written by Dominique Freeman, Director of Business Development USA, Cambridge Design Partnership
Innovation is fundamental to healthcare technology due to industry demands and the fiercely competitive nature of the international business sector. The heavily regulated environment can create longer development lead times and require increased levels of investment making breakthrough projects more difficult to justify. It is often felt within these organisations that because they operate within such a specialist field, only in house teams have the in depth knowledge required to deliver innovation effectively.
But this is not necessarily the case. There are in fact many benefits to outsourcing that staying within the industry could not bring. Leading technology and design consultancies have extremely specialist teams with expertise in niche areas and can be a highly effective way to manage new product development and growth in a healthcare organisation.
One obstacle to outsourcing is that some organisations do not realise what the potential benefits are. Some of the most compelling benefits relate to the added value of bringing in an external consultancy to compliment your existing team, as the resulting multi-disciplinary teams create new ideas and approaches and build a network of knowledge to get results fast.
Working with an external consultancy is also a tool to help optimise your return on investment in new product development. The decision to outsource will represent a significant investment, but compared with recruiting, training and managing an in-house department, outsourcing can bring a highly qualified, focused, and well-resourced team at short notice, ultimately minimising time to market and mitigating project risks. It also brings resource flexibility making it easier to optimise project portfolios and maintain the most profitable product pipeline as market conditions change.
Businesses that are thinking of outsourcing are often unsure about what point in the design cycle to approach the consultancy. The answer is to approach partners early, as it is likely that more established consultancies have valuable experience of hundreds of similar projects and can offer useful advice to help navigate around potential pitfalls.
A useful way of identifying the right partner is to use a checklist to vet potential consultancies against your organisation’s requirements. Areas to consider should include; the breadth and depth of capabilities, expertise of key personnel, track record in similar product categories, in house resources, links to manufacturing and supply chains and most importantly your ability to work with and trust their team on a personal basis.
The thought of outsourcing may seem like a daunting prospect especially in times of economic uncertainty, but this is exactly when your competitors are scaling back and you have the opportunity to take a fresh perspective and create new products ahead of market change. Finally, when the new product is launched, your own team will almost certainly have gained some new ideas and experience along the way.
Introducing Dosis - the AI powered dosing platform
Cloud-based platform Dosis uses AI to help patients and clinicians tailor their medication plans. Shivrat Chhabra, CEO and co-founder, tells us how it works.
When and why was Dosis founded?
Divya, my co-founder and I founded Dosis in 2017 with the purpose of creating a personalised dosing platform. We see personalisation in so many aspects of our lives, but not in the amount of medication we receive. We came across some research at the University of Louisville that personalised the dosing of a class of drugs called ESAs that are used to treat chronic anaemia. We thought, if commercialised, this could greatly benefit the healthcare industry by introducing precision medicine to drug dosing.
The research also showed that by taking this personalised approach, less drugs were needed to achieve the same or better outcomes. That meant that patients were exposed to less medication, so there was a lower likelihood of side effects. It also meant that the cost of care was reduced.
What is the Strategic Anemia Advisor?
Dosis’s flagship product, Strategic Anemia Advisor (SAA), personalises the dosing of Erythropoiesis Stimulating Agents (ESAs). ESAs are a class of drugs used to treat chronic anaemia, a common complication of chronic kidney disease.
SAA takes into account a patient’s previous ESA doses and lab levels, determines the patient’s unique response to the drug and outputs an ESA dose recommendation to keep the patient within a specified therapeutic target range. Healthcare providers use SAA as a clinical decision support tool.
What else is Dosis working on?
In the near term, we are working on releasing a personalised dosing module for IV iron, another drug that’s used in tandem with ESAs to treat chronic anaemia. We’re also working on personalising the dosing for the three drugs used to treat Mineral Bone Disorder. We’re very excited to expand our platform to these new drugs.
What are Dosis' strategic goals for the next 2-3 years?
We strongly believe that personalised dosing will be the standard of care within the next decade, and we’re honored to be a part of making that future a reality. In the next few years, we see Dosis entering partnerships with other companies that operate within value-based care environments, where tools like ours that help reduce cost while maintaining or improving outcomes are extremely useful.
What do you think AI's greatest benefits to healthcare are?
If designed well, AI in healthcare allows for a practical and usable way to deploy solutions that would not be feasible otherwise. For example, it’s possible for someone to manually solve the mathematical equations necessary to personalise drug dosing, but it is just not practical. AI in healthcare offers an exciting path forward for implementing solutions that for so long have appeared impractical or impossible.